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ABSTRACT
Background
New rapid syphilis tests permit simple and immediate diagnosis and treatment at a single
clinic visit. We compared the cost-effectiveness, projected health outcomes, and annual cost of
screening pregnant women using a rapid syphilis test as part of scaled-up prenatal testing to
prevent mother-to-child HIV transmission in Haiti.
Methods and Findings
A decision analytic model simulated health outcomes and costs separately for pregnant
women in rural and urban areas. We compared syphilis syndromic surveillance (rural standard
of care), rapid plasma reagin test with results and treatment at 1-wk follow-up (urban standard
of care), and a new rapid test with immediate results and treatment. Test performance data
were from a World Health Organization–Special Programme for Research and Training in
Tropical Diseases field trial conducted at the GHESKIO Center Groupe Haitien d’Etude du
Sarcome de Kaposi et des Infections Opportunistes in Port-au-Prince. Health outcomes were
projected using historical data on prenatal syphilis treatment efficacy and included disability-
adjusted life years (DALYs) of newborns, congenital syphilis cases, neonatal deaths, and
stillbirths. Cost-effectiveness ratios are in US dollars/DALY from a societal perspective; annual
costs are in US dollars from a payer perspective. Rapid testing with immediate treatment has a
cost-effectiveness ratio of $6.83/DALY in rural settings and $9.95/DALY in urban settings.
Results are sensitive to regional syphilis prevalence, rapid test sensitivity, and the return rate for
follow-up visits. Integrating rapid syphilis testing into a scaled-up national HIV testing and
prenatal care program would prevent 1,125 congenital syphilis cases and 1,223 stillbirths or
neonatal deaths annually at a cost of $525,000.
Conclusions
In Haiti, integrating a new rapid syphilis test into prenatal care and HIV testing would prevent
congenital syphilis cases and stillbirths, and is cost-effective. A similar approach may be
beneficial in other resource-poor countries that are scaling up prenatal HIV testing.
The Editors’ Summary of this article follows the references.
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New global initiatives are ﬁnancing large scale-up pro-
grams for the prevention of mother-to-child transmission of
HIV in resource-poor countries [1]. However, neonates who
avoid HIV infection are still at risk of dying from congenital
syphilis—a disease that can largely be prevented with
inexpensive penicillin treatment of the pregnant mother if
correctly diagnosed [2]. An estimated 1 million pregnancies
each year are adversely affected by syphilis due to maternal
infection, and about half of these pregnancies end in stillbirth
or neonatal death [3]. Children who survive with congenital
syphilis can suffer serious long-term adverse effects such as
mental retardation, deafness, and blindness [4–6]. Most
women in resource-poor countries receive inadequate testing
and treatment for syphilis in pregnancy, often because they
must walk many hours to the testing site and fail to return for
follow-up appointments. Thus, the substantial resources
devoted to scaling up prenatal HIV testing and treatment
services may not fully achieve the goal of reducing infant
mortality unless syphilis screening becomes more widely
available.
A rapid syphilis test with immediate results implemented in
a ﬁeld setting has the advantage of allowing women who test
positive to be treated on-site at the same visit, avoiding the
losses to follow-up associated with return visits and the
adverse outcomes associated with delayed treatment [7,8].
The World Health Organization’s Special Programme for
Research and Training in Tropical Diseases has sponsored
laboratory and ﬁeld trials of several new commercially
available rapid tests for syphilis in resource-poor countries
[9]. One of the sites for these trials is the Groupe Haitien
d’Etude du Sarcome de Kaposi et des Infections Opportu-
nistes (GHESKIO), an independent non-proﬁt center that
provides clinical and laboratory services, trains health
personnel, and conducts research in Port-au-Prince, Haiti.
Only 68% of pregnant women in Haiti have at least one
prenatal visit [10], and 66 health-care centers provide
prenatal HIV testing to about 15% of all pregnant women
in Haiti. With increased international support, the goal is to
raise the proportion receiving prenatal care with integrated
HIV testing to 85% by 2008. In urban centers, same-day
syphilis screening is generally not available, and treatment is
provided at follow-up visits. In rural areas, most pregnant
women do not have access to syphilis screening.
We used the results of the ﬁeld tests conducted at
GHESKIO [9] in a decision analytic model to evaluate the
cost-effectiveness, projected health outcomes, and annual
cost of strategies to screen Haitian pregnant women to
prevent congenital syphilis in rural and urban settings as part
of scaled-up prenatal HIV testing programs.
Methods
Overview
We developed a decision analytic model to compare
alternative strategies for adding syphilis screening to prenatal
HIV testing programs. In the model, pregnant women with
access to prenatal care are evaluated for syphilis at the ﬁrst
antenatal visit, usually at 24 wk of gestation. Depending on
the syphilis screening strategy, women are informed of the
result and initiate treatment either immediately or at the ﬁrst
follow-up visit. Treatment consists of three rounds of
benzathine penicillin G given intramuscularly at approxi-
mately 1-wk intervals in accordance with US guidelines that
are used in Haiti [11].
Health outcomes depend on whether the mother receives
treatment, and include stillbirth, neonatal death, congenital
syphilis, or an infant without congenital syphilis. To
determine cost-effectiveness ratios, we calculated disability-
adjusted life years (DALYs) for congenital syphilis cases
[12,13]. As in a previous cost-effectiveness analysis of prenatal
syphilis testing [14], we consider DALY outcomes only for the
infant and not for the mother or her sexual partners, but we
include DALYs averted by averting stillbirths (after taking
into account the risk of stillbirth from other causes). We
consider a stillbirth averted equivalent to gaining a normal
disability-adjusted life expectancy at birth in Haiti. Cost-
effectiveness ratios are in 2004 US dollars/DALY from a
societal perspective (health system and indirect patient costs),
and annual costs are in 2004 US dollars from a payer
perspective. The model was programmed using DATA Pro
Healthcare (TreeAge Software, http://www.treeage.com).
Syphilis Screening Strategies
We consider three principal syphilis screening strategies:
syndromic surveillance, rapid plasma reagin (RPR) testing
with results delivered at a follow-up visit approximately 1 wk
later, and a rapid test with immediate results (Figure 1).
Syndromic surveillance is assumed to be the standard of care
in rural settings, where most patients do not have access to
syphilis laboratory testing [15]. Syndromic surveillance is
deﬁned as a presumptive diagnosis of syphilis and subsequent
treatment based on a ﬁnding of genital ulcer disease (GUD) at
the prenatal exam. RPR testing with results delivered at a
follow-up visit is assumed to be the standard of care in urban
settings. Quantitative RPR testing with treatment based on
titer is not done in Haiti.
Three commercially available rapid syphilis tests with
immediate results were evaluated in a ﬁeld test at GHESKIO
(Determine Syphilis TP, Abbott Laboratories, http://www.
abbott.com; SD BIOLINE Syphilis 3.0, Standard Diagnostics,
http://www.standardia.com; and VISITECT Syphilis, Omega
Diagnostics,http://www.omegadiagnostics.com). These tests
detect antibodies speciﬁc to Treponema pallidum. Clinic nurses
were trained to use each rapid test; the results of the rapid
tests performed by the nurse in the ﬁeld and the results of the
RPR tests performed by a technician in the laboratory were
compared to a gold standard of a positive reading on the
Treponema pallidum haemagglutination assay (TPHA) alone; an
alternative gold standard of a positive reading on both RPR
and TPHA was also examined. Table 1 reports the evaluation
results for pregnant women for the RPR test and one of the
rapid syphilis tests compared against the TPHA gold stand-
ard; mean results for the other rapid tests generally fell within
the conﬁdence intervals used to deﬁne sensitivity analysis
ranges. To eliminate the ‘‘learning curve’’ period associated
with performing a new test, data from the ﬁrst 2 wk of ﬁeld
use of each rapid test were excluded. The sensitivity of the
rapid test on whole blood when conducted on pregnant
women in ﬁeld conditions was 83.3%, which is lower than
previously reported when the test was conducted in the
GHESKIO laboratory [9], but similar to the rapid test
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[16].
Health Outcomes
US historical data on syphilis outcomes for pregnant
women treated with benzathene penicillin-G offered the
most appropriate estimates for these outcomes in present day
Haiti (Table 1) [17]. Studies have also been conducted in
Africa on the treatment outcomes of pregnant women with a
positive syphilis test. However, RPR testing in Africa is of
highly varying quality [18,19], there is a high prevalence of
other treponemal diseases (such as yaws) that can affect RPR
test performance [7], and some pregnant women may have
been previously treated for syphilis, which could lead to a
false positive TPHA or rapid test result. Neither competing
treponemal diseases nor previous treatment for syphilis were
present in the US historical study, conducted in inner-city
Philadelphia in the 1940s, nor are they important factors in
present-day Haiti, where yaws has been eliminated and
treatment of syphilis is rare [15,20,21]. Additionally, the US
historical study reported pregnancy outcomes (including
stillbirths and neonatal deaths) for both treated and un-
treated women with syphilis and for uninfected women.
Effectiveness estimates were adjusted to account for a higher
background rate of stillbirths observed in uninfected women
in Haiti [22].
The effectiveness of penicillin treatment in preventing
congenital syphilis and stillbirths is assumed to be unaffected
by failure to complete the second and third treatments [23].
Potential health beneﬁts of second and third treatments to
the pregnant woman are not considered. Return rates for
pregnant women are 58.8% for the ﬁrst follow-up visit and
38.2% for receiving a full course of three rounds of
benzathine penicillin G [15]. All women are requested to
refer their sexual partners for treatment, and we assumed
that 42% of partners present for treatment [24]. DALYs for
children with and without congenital syphilis are calculated
based on life expectancy in Haiti and a published disability
weight for congenital syphilis of 0.315 [12,13,25]. We
conservatively assume that a child with congenital syphilis
Figure 1. Syphilis Screening Strategies
doi:10.1371/journal.pmed.0040183.g001
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decrement in quality of life. All DALYs are calculated using a
3% annual discount rate [26].
Costs
Table 2 presents direct labor and material cost model
inputs using market rates. Direct labor costs are derived from
responses provided by the clinical staff at GHESKIO to a
written survey requesting estimates of the time required
during the ﬁeld trial to conduct the test by a nurse (rapid test
on whole blood) or by a laboratory technician (batch
processing of RPR tests), and of the time required by a nurse
to draw blood and to conduct pre-test and post-test
counseling related to the syphilis test. When tests are
performed in urban settings, we assume the average nurse
labor rate of $4.91/h based on data from GHESKIO; when
tests are performed in rural settings, we assume that the
duties of a nurse would be performed by an aide-auxiliaire at
a labor rate of $0.77/h. In the base case, the cost of the rapid
test was assumed to be $1.10, the cost of the most expensive of
the three tests evaluated (range $0.39–$1.10) [9]. Treatment
costs are incurred by pregnant women diagnosed with
syphilis and by their partners who present for treatment.
Transportation, overhead, infrastructure, and training costs
are not included because we assume that these costs are
incurred by the integrated prenatal HIV testing program with
or without syphilis testing.
Costs from a societal perspective also include patient travel
to attend follow-up visits and patient time receiving counsel-
ing, testing, and treatment. For urban settings, we use data on
the place of residence of patients attending GHESKIO clinics
in 2004 and assume that 75% of patients arrive by ‘‘tap-tap’’
(local bus), 20% by taxi, and 5% on foot (A. St. Cyr and P.
Vachon, personal communication). Transportation charges
and travel times are weighted averages for patients coming
from different Port-au-Prince neighborhoods. In rural
settings, we assume that prenatal HIV testing sites include
mobile teams that would be deployed so that women could
travel on foot to a prenatal care visit (R. Berggren, personal
communication). The cost of patient time is the average
income self-reported by GHESKIO patients in 2004.
For children with congenital syphilis, the estimated addi-
tional cost of treatment in the ﬁrst year of life compared to
treatment of children without congenital syphilis is $36.50.
This is the cost of three additional clinic visits ($4.50) and two
hospitalizations ($24.00 for supplies and $8.00 for hospital
costs). Thereafter, it is assumed that children with congenital
syphilis do not receive any additional care compared to other
children in Haiti because children who survive with long-
Table 1. Model Input Variables for Population Characteristics, Test Performance, Treatment Outcomes, and DALYs
Category Variable Value Sensitivity
Analysis Range
Source
Population characteristics Prevalence of syphilis in pregnant women in rural settings 3.8% 2.0%–7.0% [28]
Prevalence of syphilis in pregnant women in urban settings 3.5% 2.0%–7.0% [28]
Prevalence of GUD in pregnant women 9.4% NA [44]
Prevalence of syphilis in pregnant women with GUD in rural and urban settings 8.7% 3.8%–23.0% [45–48]
Prevalence of syphilis in pregnant women without GUD in rural settings 3.2% Calculated
Prevalence of syphilis in pregnant women without GUD in urban settings 3.0% Calculated
Test characteristics
a Rapid test sensitivity (field conditions) 83.3% 50.1%–97.1% GHESKIO field trial
RPR test sensitivity (laboratory) 75.6% 62.2%–89.9% GHESKIO field trial
Rapid test specificity (field conditions) 98.9% 92.9%–99.9% GHESKIO field trial
RPR test specificity (laboratory) 95.7% 94.4%–98.0% GHESKIO field trial
Pregnancies resulting
in stillbirth
Mother without syphilis 9.3% 0.0%–13.9% [22]
Untreated mother with syphilis
b 28.2% 23.8% 33.6% [17,22]
Treated mother with syphilis (1–3 treatments)
b 10.1% 8.8% 12.4% [17,22]
Pregnancies resulting
in neonatal death
Mother without syphilis 2.2% 1.9%–2.5% [17]
Untreated mother with syphilis 15.6% 8.9%–16.6% [17]
Treated mother with syphilis (1–3 treatments) 1.1% 0.4%–2.7% [17]
Pregnancies resulting
in congenital syphilis
Untreated mother with syphilis 30.5% 25.4%–36.0% [17]
Treated mother with syphilis (1–3 treatments) 1.1% 0.4%–2.7% [17]
Proportion attending
follow-up visits
First follow-up visit 58.8% 40.8%–74.9% [15]
Complete treatment 38.2% 22.7%–56.4% [15]
Sexual partners 42.0% NA [24]
DALY estimates Life expectancy of normal child 50 35–60 [25]
Life expectancy of child with congenital syphilis 50 35–60 Assumption
Disability weight for congenital syphilis 0.315 0.1575–0.4725 [12]
DALYs for child with congenital syphilis
b 9.210 4.605–13.815 Calculated
DALYs for stillbirth or neonatal death
b 29.239 Calculated
aCompared to a gold standard of a positive reading on the TPHA alone.
bAdjusted for background stillbirth rate in Haiti.
NA, not available.
doi:10.1371/journal.pmed.0040183.t001
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and treatment.
Cost-Effectiveness Evaluation
Cost-effectiveness analyses were conducted by running the
model separately for rural and urban settings, because of the
differences between these settings in standards of care
(syndromic surveillance versus RPR testing) and stafﬁng
patterns (nurse versus aide-auxiliaire). All cost-effectiveness
ratios were calculated as the incremental cost per additional
DALY averted compared with the next best strategy, after
eliminating strategies because of dominance or extended
dominance [26,27]. Because DALYs are measures of health
losses, DALYs are averted (rather than saved) by effective
interventions; therefore, more effective interventions pro-
duce fewer DALYs. A lower (more attractive) cost-effective-
ness ratio minimizes the number of DALYs incurred per
dollar spent [13]. One-way and two-way sensitivity analyses
were conducted on model input variables. Test performance,
treatment efﬁcacy, and patient return rate sensitivity analysis
ranges were based on conﬁdence intervals derived from
clinical data (Table 1). Syphilis prevalence was varied over the
range observed in Haiti; life expectancy was varied by 10 y;
the congenital syphilis disability weight, labor costs, and
supply costs were varied by 50%; and the cost of the rapid test
was varied from $0.35 to $1.50.
Two alternative testing scenarios were considered that
included using the rapid test and RPR test in combination. In
the ﬁrst scenario, rapid testing with an RPR conﬁrmatory test,
patients with positive rapid test results commence treatment
immediately, but they also receive an RPR test. At the ﬁrst
follow-up visit, only patients with both positive RPR test
results and positive rapid test results continue treatment. In
the second scenario, RPR testing with a rapid conﬁrmatory
test, patients with a positive RPR test immediately receive a
rapid test at the ﬁrst follow-up visit, and the rapid test must
be positive in order for treatment to be initiated. We also
report results for a strategy of no screening and empiric
treatment for syphilis of all pregnant women presenting for
antenatal care.
Projection of National Scale-Up
We calculated the number of congenital syphilis cases,
neonatal deaths, and stillbirths avoided, and the total cost of a
national scale-up of rapid syphilis testing and treatment as
part of integrated prenatal care and HIV testing. We ran the
model separately for each of nine rural provinces (depart-
ments) and for urban settings (Port-au-Prince, Cap Haitien,
and Gonaives). We used the reported prevalence of conﬁrmed
syphilis diagnosis in pregnant women and ofﬁcial population
estimates for each location [28,29], and we multiplied the cost
and outcomes per patient tested by the number of pregnant
women with access to antenatal care. We assumed 100%
access to antenatal care in urban areas and 64% in rural
areas, based on a reported 68% national access to antenatal
care [10]. Results for the provinces are aggregated in order to
provide comparisons among four rural regions with pop-
ulations of similar sizes (central, south, north, and west) and
also include cost-effectiveness ratios from a societal perspec-
tive for each region. Costs for urban and rural regions were
calculated separately, in order to derive national program
costs for rapid tests, labor, supplies, and syphilis treatment.
Patients’ Consent and Ethics Committee Approval
The ﬁeld trial was approved by the GHESKIO Ethics
Committee and the Weill Medical College of Cornell
University Institutional Review Board, and patients provided
informed consent.
Table 2. Costs Used in Model
Category Variable Cost Source
Labor rates (US$/hour) Nurse (urban settings) $4.91 GHESKIO
Aide-auxiliaire (rural settings) $0.77 Albert Schweitzer Hospital
Laboratory technician $1.91 GHESKIO
Patient $0.075 GHESKIO
Rapid test Test (US$) $1.10 [9]
Supplies (US$) $0.17 GHESKIO
Time of nurse or aide-auxiliaire per test (minutes) 17.5 GHESKIO
RPR test Test (US$) $0.23 GHESKIO
Supplies (US$) $0.27 GHESKIO
Depreciation (US$) $0.03 [49]
Time of laboratory technician for a batch of ten tests (minutes) 37.5 GHESKIO
Syphilis treatment Benzathine penicillin G, single shot of 2.4 million units (US$) $0.14 GHESKIO
Supplies (US$ per shot) $0.07 GHESKIO
Visit time (minutes) 20.0 GHESKIO
Postnatal care (US$) Incremental cost for infant with congenital syphilis $36.50 Management and Resources for Community Health
Pre-test counseling
a 13.8 GHESKIO
Post-test counseling with positive result
a 22.5 GHESKIO
Post-test counseling with negative result
a 15.0 GHESKIO
Indirect costs (US$) Patient time for treatment $0.025 GHESKIO
Patient travel costs for follow-up visit (urban settings)
b $1.58 GHESKIO
Patient travel costs for follow-up visit (rural settings)
b $0.13 Management and Resources for Community Health
aCounseling related to syphilis test (minutes), incremental to HIV counseling.
bIncludes cost of travel time.
doi:10.1371/journal.pmed.0040183.t002
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Cost-Effectiveness
In rural settings, syndromic surveillance costs $0.48 per
patient tested, RPR testing costs $1.43 (an incremental $0.95
versus syndromic surveillance), and rapid testing costs $2.15
(an incremental $0.72 versus RPR testing) (Table 3). RPR
testing averts an incremental 0.090 DALYs per patient tested
versus syndromic sureveillance, and rapid testing averts an
additional incremental 0.154 DALYs versus RPR testing. The
cost-effectiveness ratio for RPR testing versus syndromic
surveillance is $10.64/DALY; the cost-effectiveness ratio for
rapid testing versus syndromic surveillance is $6.83/DALY;
and the cost-effectiveness ratio for rapid testing versus RPR
testing is $4.62/DALY. Rapid testing has a lower (i.e., more
attractive) cost-effectiveness ratio than RPR testing because it
has greater absolute beneﬁts in terms of DALYs averted
compared to syndromic surveillance, despite its higher cost. It
therefore represents a more efﬁcient use of resources. The
RPR testing strategy is eliminated because of extended
dominance; it is less efﬁcient than a mixed strategy of the
rapid test and syndromic surveillance [27]. Compared to
syndromic surveillance, for every 1,000 women in rural
settings who receive the rapid test, 6.0 congenital syphilis
cases, 6.5 stillbirths, and 4.2 neonatal deaths would be
avoided.
In urban settings, RPR testing costs $5.51 per patient
tested, and rapid testing costs $6.96 (an incremental $1.45)
(Table 3). Rapid testing averts an incremental 0.146 DALYs
compared to RPR testing, and the cost-effectiveness ratio for
rapid testing is $9.95/DALY. Compared to RPR testing, for
every 1,000 women in urban settings who receive the rapid
test, 1.4 congenital syphilis cases, 1.0 stillbirths, and 1.1
neonatal deaths would be avoided.
In one-way sensitivity analyses, results are sensitive to the
prevalence of syphilis and the sensitivity of the rapid test
(Table 4). Assuming 2% prevalence of syphilis in pregnant
women (versus 3.7% national prevalence), the cost-effective-
ness ratios are $19.93/DALY in rural settings and $17.32/
DALY in urban settings. Assuming 7% prevalence of syphilis
in pregnant women, the cost-effectiveness ratios are $2.75/
DALY in rural settings and $4.93/DALY in urban settings.
Assuming 50% sensitivity of the rapid test (versus 83.3% in
the ﬁeld trial), the cost-effectiveness ratios compared to the
standard of care are $15.74/DALY in rural settings and $68.98/
DALY in urban settings. Assuming 97% sensitivity of the
rapid test, the cost-effectiveness ratios are $5.44/DALY in
rural settings and $7.35/DALY in urban settings.
In two-way analyses, the impact of the sensitivity of the
rapid test on cost-effectiveness results is affected by the
probability that the pregnant woman returns for follow-up
visits, the prevalence of syphilis, and the cost of the test.
Assuming a cost-effectiveness threshold of $10/DALY, rapid
testing remains the preferred strategy in rural settings as long
as its sensitivity is 75% and the return rate at the ﬁrst
follow-up visit is 75% (Figure 2A). At a price of $1.30, rapid
testing remains the preferred strategy as long as its sensitivity
is 70%, and at a price of $0.45 the rapid test remains the
preferred strategy as long as its sensitivity is 50% (Figure
2B).
Results are more sensitive to nurse labor rates in the urban
setting than in the rural setting. In the urban setting, when
the nurse labor rate is varied by 50% the cost-effectiveness
ratio varies from $3.42/DALY to $16.52/DALY. In the rural
setting, the nurse labor rate must be 2.4 times higher than the
base case in order for the cost-effectiveness ratio to exceed
$10/DALY. When the sensitivity of the rapid test is low, cost-
effectiveness ratios are higher (less attractive) in urban
settings, where the comparator is the RPR test, than in rural
settings, where the comparator is syndromic surveillance.
Results are not strongly affected by the speciﬁcity of the
rapid test within the conﬁdence interval observed in the ﬁeld
test nor by the partner return rate nor by test and treatment
costs (Table 4). Results are not affected by the choice of gold
standard; using the gold standard of a positive ﬁnding on
both TPHA and RPR tests, the cost-effectiveness ratios are
$5.27/DALY in rural areas and $10.00/DALY in urban areas.
Neither of the combination test scenarios is more cost-
effective than the rapid test alone. In the ﬁrst scenario, when
RPR testing is used as a conﬁrmatory test and treatment is
discontinued if the RPR test is negative, the cost saving from
eliminating unnecessary follow-up treatments for false
positive rapid tests is offset by the additional cost of the
RPR test unless the speciﬁcity of the rapid test is poor. In the
second scenario, when the rapid test is used only as a
conﬁrmatory test on patients with a positive RPR test, the
Table 3. Cost-Effectiveness Results: Costs, DALYs, and Cost-Effectiveness per Maternal Patient Tested
Setting Strategy Cost (US$) DALYs Incremental Cost Incurred
versus Standard of Care (US$)
Incremental DALYs Averted
versus Standard of Care
Cost-Effectiveness
(US$/DALY)
Rural Syndromic surveillance
a 0.48 3.620
RPR test 1.43 3.530 0.95 0.090 Extended dominance
b
Rapid test 2.15 3.376 1.67 0.244 6.83
Urban RPR test
a 5.51 3.517
Rapid test 6.96 3.371 1.45 0.146 9.95
Numbers may not add or divide due to rounding. Because DALYs are measures of health losses, DALYs are averted (rather than saved) by effective interventions; therefore, more effective
interventions produce fewer DALYs.
aStandard of care.
bThe cost-effectiveness ratio for the RPR test versus syndromic surveillance is $10.64/DALY; the cost-effectiveness ratio for the rapid test versus syndromic surveillance is $6.83/DALY; and
the cost-effectiveness ratio for the rapid test versus the RPR test is $4.62/DALY. The rapid test has a lower (i.e., more attractive) cost-effectiveness ratio than the RPR test because it has
greater absolute benefits in terms of DALYs averted compared to syndromic surveillance, despite its higher cost. It therefore represents a more efficient use of resources. The RPR test
strategy is eliminated because of extended dominance; it is less efficient than a mixed strategy of the rapid test and syndromic surveillance [27].
doi:10.1371/journal.pmed.0040183.t003
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the initial visit; this strategy always has the highest (i.e., least
attractive) cost-effectiveness ratio. Empiric treatment without
screening has a cost-effectiveness ratio of $2.41/DALY
compared to syndromic surveillance in rural settings and
$2.05/DALY compared to RPR testing in urban settings, and
in sensitivity analyses it consistently has the lowest cost-
effectiveness ratio. However, the feasibility and additional
consequences of wide antibiotic exposure associated with this
strategy were not evaluated.
National Scale-Up
Integrating rapid syphilis screening with immediate treat-
ment into a scaled-up national HIV testing program for the
estimated 202,000 pregnant women in Haiti who currently
have access to prenatal care (68% of all pregnancies) would
require annually screening approximately 168,000 pregnant
women in rural areas, 35,000 women in urban areas, and
85,000 sexual partners. The beneﬁts would include avoiding
1,129 congenital syphilis cases, 786 stillbirths, and 437
neonatal deaths annually. From the payer perspective, the
direct cost of this program would be $525,000 annually, of
which 46% would be for rapid tests, 42% for labor, 7% for
supplies, and 6% for other costs (including the costs of
penicillin, partner treatment, and treatment of congenital
syphilis cases). Table 5 presents the projected national scale-
up results for all urban areas and the four rural regions. The
cost per adverse outcome (stillbirth, neonatal death, or
congenital syphilis case) avoided varies from $108 in the
rural region with the highest syphilis prevalence to $218 in
the rural region with the lowest prevalence; similarly, the
regional cost-effectiveness ratios vary from $4.78/DALY to
$10.79/DALY. Costs are highest in urban settings, because of
the higher labor cost for nurses, and the incremental beneﬁt
is lower because the comparator in urban settings is RPR
testing (instead of syndromic surveillance); about 90% of the
adverse outcomes avoided occur in rural areas.
Discussion
In an era when substantial resources are going towards the
prevention of mother-to-child transmission of HIV, there is
an opportunity to integrate these efforts with programs to
prevent congenital syphilis [30,31]. New rapid syphilis tests
can be included in prenatal HIV testing programs operating
in settings without access to same-day laboratory results. The
current study demonstrates that such a prenatal syphilis
screening strategy in Haiti using new rapid tests that permit
same-day diagnosis and treatment have attractive incremen-
tal cost-effectiveness ratios when compared with current
practice, which relies upon syndromic management or RPR
testing with treatment at a follow-up visit. We project that
integrating rapid syphilis screening into a scaled-up national
program to test pregnant women for HIV in Haiti would
prevent over 1,100 cases of congenital syphilis and over 1,200
neonatal deaths or stillbirths annually, mostly in rural areas.
The cost-effectiveness of implementing this strategy is
approximately $7.00/DALY in rural settings and $10.00/DALY
in urban settings. The cost to prevent an adverse outcome of
syphilis in pregnancy, including a stillbirth, a neonatal death,
or an infant with congenital syphilis, is $108–$218 per adverse
outcome in rural settings. The results of our analysis suggest
that empirically treating all pregnant women with penicillin
may be more cost-effective than the current practice in
settings where syphilis testing is not feasible, even though
mass treatment campaigns have had mixed success in other
Table 4. One-Way Sensitivity Analyses for Cost-Effectiveness Results Compared to the Rural and Urban Standards of Care
Category Variable Cost-Effectiveness Ratio Range ($/DALY)
Rural Settings Urban Settings
Population characteristics Prevalence of syphilis in pregnant women 2.75–19.93 4.93–17.73
Prevalence of syphilis in pregnant women with GUD 5.53–17.81 NA
Test characteristics Rapid test sensitivity (field conditions) 5.44–15.74 7.35–68.98
RPR test sensitivity (laboratory) NA 8.31–12.70
Rapid test specificity (field conditions) 6.75–7.27 9.37–13.55
RPR test specificity (laboratory) NA 9.43–10.92
Pregnancies resulting in stillbirth Untreated mother with syphilis 6.23–7.41 9.07–10.85
Treated mother with syphilis (1–3 treatments) 6.60–7.28 9.63–10.63
Pregnancies resulting in neonatal death Untreated mother with syphilis 6.73–7.62 9.82–11.17
Treated mother with syphilis (1–3 treatments) 6.68–7.07 9.76–10.33
Pregnancies resulting in congenital syphilis Untreated mother with syphilis 6.52–7.12 9.58–10.35
Treated mother with syphilis (1–3 treatments) 6.77–6.96 9.90–10.15
Proportion attending follow-up visits First follow-up visit 6.78–6.88 9.89–25.92
Complete treatment NA 9.68–10.22
DALY estimates Life expectancy of normal child 6.40–8.40 9.35–12.28
Life expectancy of child with congenital syphilis 5.09–9.42 7.44–13.75
Disability weight for congenital syphilis 6.14–7.69 8.97–11.25
Costs (varied 6 50%) Labor cost/duration of visits 5.68–7.97 3.88–16.06
Rapid test cost 3.75–8.47 4.81–12.72
Syphilis treatment cost 6.35–7.31 9.51–10.43
Incremental cost for infant with congenital syphilis 6.45–7.28 9.59–10.42
See Table 1 and text for ranges.
NA, Not applicable.
doi:10.1371/journal.pmed.0040183.t004
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Cost-Effectiveness of Rapid Syphilis Testingsettings [32–34]. However, our analysis did not include the
potential consequences of widespread antibiotic use in the
empiric treatment strategy.
The cost-effectiveness ratios of $7.00/DALY to $10.00/
DALY for rapid syphilis testing fall well below two cost-
effectiveness thresholds that have been recommended for
health interventions in resource-poor countries: $50/DALY
[35] and the average per-person gross domestic product in
the country where the intervention is being implemented (in
Haiti, $440) [36,37]. In addition, the cost-effectiveness ratios
are similar to or lower than ratios reported for HIV
interventions in sub-Saharan Africa including HIV testing
in Kenya ($12.77/DALY in 1998 US dollars) and Tanzania
($17.78 in 1998 US dollars) [38], improved treatment of
sexually transmitted diseases to prevent HIV infection in
Tanzania ($10.33/DALY in 1993 US dollars) [39], and a 1999
study of nevirapine to prevent mother-to-child HIV trans-
mission ($5.25–$19.18/DALY) [40].
Terris-Prestholt et al. found a similar cost-effectiveness
ratio for a same-day RPR antenatal syphilis screening
program in Tanzania ($10.56/DALY in 2001 US dollars) and
estimated that the cost-effectiveness of this program in a
variety of settings in sub-Saharan Africa is $3.97–$18.73/
DALY in 2001 US dollars [14]. However, ﬁeld experience in
Figure 2. Two-Way Sensitivitity Analyses
Preferred syphilis screening strategy for rural settings assuming a cost-effectiveness threshold of $10/DALY (A) varying the return rate for the first
follow-up visit and the sensitivity of the rapid test, and (B) varying the cost and sensitivity of the rapid test.
doi:10.1371/journal.pmed.0040183.g002
Table 5. Projected Outcomes, Costs, and Incremental Cost-Effectiveness Ratios for Integrating Rapid Syphilis Screening into Prenatal
HIV Testing Programs in Haiti
Projection Rural Region Urban Areas
Central South North West All
Pregnancies with access to care 36,625 40,362 33,692 57,205 34,460
Prevalence of syphilis in pregnant women 4.8% 4.6% 3.3% 2.8% 3.5%
Stillbirths avoided 209 220 116 156 85
Neonatal deaths avoided 116 122 64 87 48
Congenital syphilis cases avoided 300 316 166 224 123
Total payer cost (US$) 75,179 82,606 67,307 113,290 186,637
Payer cost per adverse outcome (stillbirth, neonatal death,
or congenital syphilis) avoided (US$)
108 113 174 218 791
Incremental cost
a (US$) 58,618 65,024 57,150 98,762 49,956
Incremental DALYs averted 12,263 12,923 6,802 9,153 5,017
Cost/DALY
a (US$) 4.78 5.03 8.40 10.79 9.95
aFrom a societal perspective.
doi:10.1371/journal.pmed.0040183.t005
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Cost-Effectiveness of Rapid Syphilis TestingAfrica has shown that there are substantial operational
challenges to implementing same-day antenatal syphilis
screening using RPR including adequate training, continuity
of supplies, need for electricity, quality control, and super-
vision [18,19]. In addition, not all women are willing to wait at
the testing site to obtain RPR results [18], and batch
processing of RPR tests can extend waiting times. Implement-
ing rapid syphilis screening in the context of prenatal HIV
testing can address many of these challenges. Rapid syphilis
tests require less training and supervision than on-site RPR
tests, and results and treatment are available immediately.
Logistical support and infrastructure provided by the
prenatal HIV programs can be leveraged to address many
of the remaining gaps [41]. Because the prenatal HIV
programs already incur the cost of this support, the cost-
effectiveness ratio for integrated syphilis testing is more
attractive than it would be for a separate ‘‘vertical’’ program.
There are several limitations to our analysis. Years of life
lost due to stillbirths avoided are included in our evaluation;
stillbirths are not routinely included in DALY calculations
and excluding them would have resulted in substantially less
attractive cost-effectiveness ratios [14]. We used data from a
historical US study to project treatment efﬁcacy, which had
the advantage of allowing us to project congenital syphilis
cases avoided instead of using a proxy such as low birth
weight. However, these data may not be representative of
outcomes actually experienced in Haiti despite adjustments
for the higher background stillbirth rate in Haiti. The
counseling related to the syphilis test that occurred in the
ﬁeld trial may be more extensive than occurs in practice, but
cost-effectiveness ratios in rural settings are not affected
because of the low labor costs; in urban settings the cost-
effectiveness ratios would be less attractive if less counseling
occurs. Indirect costs for patient time and transportation
were low, but may not fully reﬂect the personal costs
associated with syphilis testing and treatment due to lost
productivity and family income. Training and other start-up
costs incurred by HIV testing programs were assumed to be
unaffected by adding syphilis testing; however, additional
start-up costs may be incurred in other settings where HIV
testing is already ongoing.
The ﬁeld performance of the rapid test might be improved
with more intensive training and quality assurance activities,
resulting in a more attractive cost-effectiveness ratio, but we
did not evaluate the cost-effectiveness of such a program.
RPR test performance at GHESKIO may reﬂect higher levels
of training for its laboratory personnel compared to other
urban laboratories. RPR testing in rural areas may be more
expensive and less effective than our estimate because of
distances between testing sites and laboratories. Because the
rapid test is a trepenomal test and trepenomal antibodies can
persist for life in successfully treated patients [7], the
speciﬁcity of the rapid test may deteriorate in the future if
treatment of syphilis becomes more widespread in Haiti. This
would result in overtreatment and less attractive cost-
effectiveness ratios. Using the RPR test as a conﬁrmatory
test may be cost-effective in settings where there is a high
prevalence of previously treated syphilis or other endemic
treponemal diseases.
Integrating rapid syphilis testing and immediate treatment
into prenatal care and HIV testing in Haiti would prevent
congenital syphilis cases and stillbirths, and is cost-effective.
At an incremental direct cost of only $525,000 annually, the
impact of adding rapid syphilis screening to the prenatal HIV
testing budget appears quite modest, representing less than
1% of the $55.6 million US President’s Emergency Plan for
AIDS Relief budget for Haiti in ﬁscal year 2006 [42]. Using
information on syphilis prevalence rates, test performance,
and return rates for follow-up antenatal visits, projected
results can help set priorities for scale-up implementation. In
our analysis, these projections indicate a focus on implement-
ing rapid syphilis testing in rural regions that have high
syphilis prevalence and lack RPR testing capability.
Worldwide, effective syphilis screening could prevent more
than 500,000 fetal deaths per year, primarily in sub-Saharan
Africa; this result is similar to the potential beneﬁts from
preventing mother-to-child transmission of HIV [43]. We
believe our ﬁndings are generalizable to HIV scale-up
programs in Africa and other resource-poor settings, because
in our model the cost-effectiveness ratio for rapid syphilis
testing remains attractive when syphilis prevalence is varied,
when rapid testing is compared to either RPR testing or
syndromic surveillance, and in both rural and urban areas.
Prenatal care with integrated HIV and syphilis screening will
have a powerful impact on improving health outcomes in
Haiti and can be a model for similar programs throughout
the world.
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Cost-Effectiveness of Rapid Syphilis TestingEditors’ Summary
Background. Congenital syphilis (syphilis that is passed on from a
woman infected with the disease to her unborn baby) is a major
preventable public health problem. Around half of all pregnancies
among women infected with syphilis result in stillbirth or death of the
baby shortly after birth. However, it should be possible to reduce the
health burden of congenital syphilis if infections among pregnant
women could be quickly and accurately diagnosed. In resource-poor
countries, many syphilis infections go undiagnosed, because the tests
that are normally used involve sending samples away to a laboratory for
processing. This means that the diagnosis can only be confirmed, and
treatment started, at the next available visit. As a result, there is a delay in
starting antibiotic treatment, and some women may never receive their
intended treatment at all if they cannot return for their follow-up visit.
However, new tests are available that don’t involve cold storage of
reagents or electrical equipment, and these can be used to give an
immediate result about syphilis infection even in rural or resource-poor
settings. Currently, global initiatives are underway to ensure many more
pregnant women are tested for HIV and to reduce the risk of HIV being
passed on from a woman to her baby. These initiatives could provide an
important opportunity for carrying out widespread immediate screening
for syphilis during pregnancy as well. Such screening might then help
reduce infant deaths substantially.
Why Was This Study Done? Field trials evaluating rapid syphilis tests
have already been carried out by the World Health Organization’s Special
Programme for Research and Training in Tropical Diseases. One such
trial, carried out in Port-au-Prince, Haiti, evaluated the success of three
different rapid syphilis tests as compared to two ‘‘gold standard’’ tests
(older tests that are generally considered reliable, but which don’t give
an immediate result). These researchers wanted to use data from these
trials to compare costs and predicted health outcomes of including
different types of syphilis screening as part of scaled-up prenatal care.
Specifically, the researchers wanted to find out whether including rapid
syphilis testing as part of universal prenatal care would be cost-effective
and whether it would reduce the rate of stillbirths and congenital
syphilis.
What Did the Researchers Do and Find? This research was based on
data from the field trials previously carried out in Haiti. The data from
these trials were used to create a model comparing three different
strategies for screening pregnant women for syphilis infections. The
three strategies were as follows: checking for the symptoms of syphilis
(assumed to be the standard of care in rural areas); standard testing for
antibody response to the syphilis bacterium, after which treatment can
be provided at follow-up a week later (assumed to be the standard of
care in urban areas); and, finally, rapid testing that gives an immediate
result. For each strategy, the researchers predicted what the health
outcomes would be. These outcomes are summarized in ‘‘disability-
adjusted life years’’ (DALYs) that reflect the number of years of healthy
life lost due to congenital syphilis among newborn babies, the number
of stillbirths, and the number of neonatal deaths. Cost-effectiveness of
each strategy was also worked out by dividing the additional costs of
testing and treatment for each strategy by the number of DALYs avoided
using that screening method compared to the next most expensive
alternative. Under the model, urban and rural settings were looked at
separately. Immediate testing was more expensive than either standard
testing or checking for symptoms, but emerged as more cost-effective
than standard testing in rural settings; the immediate test would cost an
additional $7–$10 per disability-adjusted life year compared to the
current rural or urban standard of care. The researchers predicted that if
immediate syphilis testing were provided to all pregnant women in Haiti
who currently have access to prenatal care, over 1,000 congenital syphilis
cases would be avoided, along with over 1,000 stillbirths and neonatal
deaths, at a yearly cost of $525,000.
What Do These Findings Mean? This model suggests that including
rapid syphilis testing as part of current global initiatives for preventing
mother-to-child transmission of HIV could substantially reduce infant
deaths. The strategy is also likely to be cost-effective.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040183.
 MedlinePlus encyclopedia entry on congenital syphilis
 Information from the World Health Organization about congenital
syphilis, including information about screening programs and new
screening tests
 A report is also available from the Special Programme for Research and
Training in Tropical Diseases regarding rapid syphilis tests
 AVERT, an international AIDS charity, provides information about
preventing mother-to-child transmission of HIV
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